ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Upregulation of miR-132 expression in glioma and its clinical significance.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Review
- A five-CpG signature of microRNA methylation in non-G-CIMP glioblastoma.CNS neuroscience & therapeutics · 2019Article
- LncRNA SNHG5 affects cell proliferation, metastasis and migration of colorectal cancer through regulating miR-132-3p/CREB5.Cancer biology & therapy · 2019Article
- Preoperative Immune Response is Associated with Perioperative Transfusion Requirements in Glioma Surgery.Journal of Cancer · 2019Article
- MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1.Acta pharmacologica Sinica · 2018Article
- Human thymic stromal lymphopoietin promotes the proliferation and invasion of cervical cancer cells by downregulating microRNA-132 expression.Oncology letters · 2017Article
- Oncogenic miR‑132 sustains proliferation and self‑renewal potential by inhibition of polypyrimidine tract‑binding protein 2 in glioblastoma cells.Molecular medicine reports · 2017Article
- Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma.Experimental and therapeutic medicine · 2016Article
- MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.Cancer medicine · 2016Review
- miR-132 mediates a metabolic shift in prostate cancer cells by targeting Glut1.FEBS open bio · 2016Article
- miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells.American journal of translational research · 2016Article
- An Encapsulation of Gene Signatures for Hepatocellular Carcinoma, MicroRNA-132 Predicted Target Genes and the Corresponding Overlaps.PloS one · 2016Article
- MicroRNA-132 inhibits cell growth and metastasis in osteosarcoma cell lines possibly by targeting Sox4.International journal of oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miR-132 was found to be overexpressed in glioma; however, its clinical significance has not been investigated. In the present study, we evaluated the association between miR-132 and clinicopathological parameters and prognosis. Quantitative real-time PCR was used to analyze the expression of miR-132 in 113 cases of glioma and 36 cases of normal brain tissues. The association of miR-132 expression with clinicopathological factors and prognosis of glioma patients were analyzed. The expression levels of miR-132 were significantly higher in glioma tissues than that in normal brain tissues (mean ± SD, 4.448 ± 1.857 vs. 1.936 ± 0.543; P < 0.001). The miR-132 expression level was classified as high or low in relation to the median value. High expression of miR-132 was found to significantly correlate with KPS score (P = 0.001); extent of resection (P = 0.009), and WHO grade (P < 0.001). Kaplan-Meier analysis with the log-rank test indicated that high miR-132 expression had a significant impact on overall survival (17.3 vs. 56.2 %; P = 0.04) and progression-free survival (11.7 vs. 50.5 %; P = 0.012). In conclusion, this study identified high miR-132 expression as a biomarker of poor prognosis in patients diagnosed with glioma.
Indexed as
Identifiers
25234714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.